Alexion Pharmaceuticals, Inc.
NASDAQ: ALXN
$182.50
+$0.00 (+0.0%)
Closing Price on July 28, 2021
ALXN Articles
A new research report from Cowen focuses on the top biotech stocks to buy before second-quarter earnings are reported.
Published:
24/7 Wall St. has reviewed the short interest in top biotech companies, without focusing on speculative companies.
Published:
The short interest data are out for the June 15 settlement date, and overall, short interest in the selected biotech stocks was mixed.
Published:
In the S&P 500, some stocks had significant moves this past week, and some were on exponential volume spikes as well.
Published:
24/7 Wall St. has put together a list of companies that have outperformed the market this past week.
Published:
The May 29 short interest data have been compared with the previous figures, and for most of the selected biotech stocks, short interest has decreased.
Published:
The short interest data are out for the May 15 settlement date. Biotech companies are considered a riskier group of stocks.
Published:
The short interest data are out for the April 30 settlement date, and for most of the selected biotech stocks, short interest is down.
Published:
A new research note from SunTrust Robinson Humphrey mentions four stocks that they think could possibly get swept up in the biotech M&A excitement.
Published:
In a new report, Deutsche Bank acknowledges that while the industry has shown recent weakness, now may be just the right time to add biotech stocks.
Published:
Biotech giant Alexion Pharmaceuticals announced Wednesday morning that it will acquire Synageva BioPharma.
Published:
The short interest data are out for the April 15 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Published:
The March 31 short interest data have been compared with the March 13 figures, and for most of the selected biotech stocks, short interest has increased.
Published:
The March 13 short interest data in top biotechs have been compared with the end of February figures, and across the board all the selected stocks have seen their short interest increase.
Published:
Wells Fargo released a report Wednesday that considers the future of major biotech companies in relation to the weak euro.
Published: